Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 7/20 | 0.67 |
| ▸ | EGLN1 | Q9GZT9 | 3/20 | 0.61 |
| ▸ | CCR3 | P51677 | 1/20 | 0.53 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.53 |
| ▸ | DPP4 | P27487 | 2/20 | 0.52 |
| ▸ | FASN | P49327 | 1/20 | 0.51 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.50 |
| ▸ | AR | P10275 | 1/20 | 0.50 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.49 |
| ▸ | VNN1 | O95497 | 1/20 | 0.49 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13162005 | 0.84 | NAMPT (0.59) | NAMPTEGLN1FASNVNN1 | |
| SCHEMBL12093537 | 0.83 | MMP13 (0.61) | NAMPTHDAC4 | |
| SCHEMBL23630645 | 0.82 | NAMPT (0.60) | NAMPTHDAC4 | |
| SCHEMBL1448089 | 0.82 | NAMPT (0.57) | NAMPTHDAC4 | |
| SCHEMBL22122859 | 0.82 | NAMPT (0.66) | NAMPTHDAC4 | |
| SCHEMBL3709218 | 0.82 | NAMPT (1.00) | NAMPT | |
| SCHEMBL19226529 | 0.81 | NAMPT (0.59) | NAMPTHDAC4 | |
| SCHEMBL12090016 | 0.80 | NAMPT (0.58) | NAMPTHDAC4 | |
| SCHEMBL16109197 | 0.78 | EGLN1 (0.70) | NAMPTEGLN1 | |
| SCHEMBL3709083 | 0.78 | NAMPT (1.00) | NAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2822656-B1 | 3-ARYL-5-SUBSTITUTED-ISOQUINOLIN-1-ONE COMPOUNDS AND THEIR THERAPEUTIC USE | CANCER RES INST ROYAL (GB) | 2016-10-19 | — | — | EP | disclosed |
| US-9193689-B2 | 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2015-11-24 | — | — | US | disclosed |
| US-20150099732-A1 | 3-ARYL-5-SUBSTITUTED-ISOQUINOLIN-1-ONE COMPOUNDS AND THEIR THERAPEUTIC USE | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2015-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150099732-A1 | 3-ARYL-5-SUBSTITUTED-ISOQUINOLIN-1-ONE COMPOUNDS AND THEIR THERAPEUTIC USE | TNKS, TNKS2, PARP11 | NAMPT 401/4885EGLN1 513/4885CCR3 4202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.